Business and Finance

Meanwhile, drugmakers ramp up US manufacturing investments to navigate policy shifts and protect supply chain resilience, as the Trump administration enacted tariff rates between 10% to 50% on various trading partners early this morning.

In the final part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, outlines practical, cost-conscious strategies for reducing Scope 3 emissions in pharma supply chains, from smarter warehouse lighting and returnable cold chain packaging, to order consolidation and AI-enabled delivery optimization.

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect patients from unapproved compounded semaglutide products by targeting pharmacies, telehealth providers, and deceptive marketing practices that compromise safety, mislead consumers, and violate FDA regulations.

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses how the pharmaceutical industry is balancing high-cost innovation, especially in obesity and metabolic disease, with payer demands for cost containment, highlighting the growing role of biosimilars and future generics in offsetting spend.

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve access, reduce side effects, and support sustainable weight loss.

In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, shares how he foresees the One Big Beautiful Bill Act reshaping prescription drug spending, and what strategies pharmaceutical companies adopt to mitigate its potential impact on innovation, R&D investment, and M&A activity.

In the fourth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a new rare disease treatment from Sanofi one month prior.

Is the industry ready for the Aug. 1 deadline of when these levies go into effect?

A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.

In the final part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, discusses the potential repercussions of telehealth companies selling GLP-1s.

The new deal imposes 15% tariffs on most EU exports, including pharmaceuticals.

As new pricing and trade policies take shape, 60% of life sciences and healthcare executives anticipate business disruption, according to a new survey from Deloitte.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, covers the operational or strategic steps that pharma executives ought to be taking now in order to mitigate risks while awaiting clarity on tariff implementation.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, comments on how pharma companies should prioritize reshoring strategies in response to these tariff threats, especially when infrastructure isn’t yet in place.

Meanwhile, President Trump continues to push reciprocal levies and reshoring efforts, while pharma prepares for escalating costs.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, describes the immediate and long-term impacts of this potential levy on pharma imports.

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.

The acquisition merges eBlu’s automation platform with Knipper’s nationwide distribution network, streamlining benefit verification, prior authorization, and patient onboarding while reducing administrative burdens for specialty providers.

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined.

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.

Why startups and life sciences companies should approach this booming sector with extreme caution.

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.